Blarcamesine works better when taken earlier in Alzheimer's: Study
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, announced by co-developers Biogen and Eisai, applies to those who first receive at least 1.5 years of the intravenous version. The approval gives patients the option to continue infusions into […] The post Leqembi OK’d as under-the-skin autoinjector for early Alzheimer’s appeared first on ...| Alzheimer's News Today – The Web's Daily Resource for Alzheimer's News
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
